The document from the World Health Organization (WHO) titled “Second meeting of the International Health Regulations (2005) Emergency Committee regarding the upsurge of mpox – 2024” provides an important update on the global response to the mpox outbreak. It outlines several key initiatives and recommendations designed to enhance access to innovative healthcare products for mpox. The focus on mpox is crucial given its rapid spread and impact on public health.
The WHO Director-General declared the mpox outbreak a Public Health Emergency of International Concern (PHEIC) due to its fast transmission, particularly in the Democratic Republic of the Congo (DRC) and neighboring regions, along with the emergence of a new sexually transmissible strain of the monkeypox virus.
The WHO Director-General initiated the Emergency Use Listing (EUL) process for mpox vaccines. This action is designed to expedite vaccine access for lower-income countries lacking national regulatory approval.
WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommends two vaccines currently used for mpox. WHO-listed national regulatory authorities and individual countries, including Nigeria and the DRC, have approved these vaccines.
WHO is intensifying efforts through coordinated international action to assist countries in ending the outbreaks. This approach involves close collaboration with communities and governments, where country teams work on the frontlines to strengthen measures against mpox.
The Director-General, upon the IHR Emergency Committee’s advice, will issue temporary recommendations to countries. These recommendations aim to boost preparedness, surveillance, and response capabilities for the mpox outbreak.
WHO demonstrates its commitment to ensuring equitable access to essential healthcare products, including diagnostics and treatments, for the impacted countries through its emphasis on a coordinated international response, even though the document does not explicitly detail new initiatives for diagnostic tools and treatments.
The WHO’s response to the mpox outbreak includes initiatives aimed at enhancing access to innovative healthcare products, particularly vaccines. These initiatives focus on emergency use listings, international coordination, and tailored recommendations to support lower-income countries in obtaining these critical healthcare products. Access to innovative healthcare products for mpox is vital for effective management of this public health challenge.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
#SyenzaNews #globalhealth #healthcareInnovation
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
#SyenzaNews #globalhealth #HealthcareInnovation
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
